VIDA® Diagnostics' Software, Apollo®, Installed at U of Florence (Italy)
VIDA® Diagnostics’ quantitative pulmonary imaging software, Apollo®, was recently installed at the University of Florence, Italy, for usage in clinical assessment of Chronic Obstructive Pulmonary Disease (COPD) phenotypes.
Apollo is installed in the Respiratory Pathophysiology Service of the University Hospital of Florence which is connected to the Department of Diagnostic Radiology of the University. Headed by leading clinician Massimo Pistolesi, MD, Professor of Respiratory Medicine, Department of Internal Medicine, University of Florence, Apollo will assess patients with various airway and parachymal phenotypes of COPD, and aid the physician to define treatment plans and assess post-treatment patient follow-up to determine procedure success.
"The emergence of pulmonary quantitative imaging into routine clinical use is a turning point for the pulmonologist treating the challenging, highly co-morbid patient population with lung disease," stated Dr. Massimo Pistolesi. “The strong collaboration between pulmonary and radiology departments at the University Hospital of Florence leads to successful clinical quantitative imaging, directly improving patient care.”
“VIDA is proud to be in the forefront of the emergence of quantitative pulmonary analysis for patient evaluation, treatment planning and follow-up," said Susan A. Wood, Ph.D., VIDA Diagnostics’ President and Chief Executive Officer. “We are pleased to have Apollo chosen as the platform in this translational work.”
Apollo® is VIDA’s pulmonary image analysis solution designed to assess pulmonary disease objectively and repeatedly with unprecedented speed and accuracy. Used for the early detection, evaluation and treatment planning of pulmonary disease including COPD, emphysema, lung cancer, and asthma; VIDA's analysis methodology has been successfully tested in multiple academic and clinical trials. Apollo recently received CE certification for clinical use in the European Economic Area (EEA) and Switzerland.